However, we believe that options for clinical interventions should be based on inhibition of Rho and Rock, because they represent the central hub in the regulation of anchorage-independent tumor growth and metastasis of E-cadherin mutant breast cancer. The gene discussed is CDH1; the disease is neoplasm.